EIF4A1P4: A Potential Drug Target and Biomarker (G728698)

Target Name: EIF4A1P4

NCBI ID: G728698

EIF4A1P4

Other Name(s): Eukaryotic translation initiation factor 4A1 pseudogene 4 | eukaryotic translation initiation factor 4A1 pseudogene 4

EIF4A1P4: A Potential Drug Target and Biomarker

Eukaryotic translation initiation factor 4A1 pseudogene 4 (EIF4A1P4) is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. It is a key regulator of the initiation of protein translation, which is the process by which mRNA is translated into functional proteins. EIF4A1P4 is expressed in most eukaryotic cells and has been implicated in various cellular processes, including cell growth, apoptosis, and translation of membrane proteins.

Recent studies have identified EIF4A1P4 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its involvement in various cellular processes that are disrupted in these diseases, providing a potential therapeutic approach.

Drug Target Potential

EIF4A1P4 has been identified as a potential drug target due to its involvement in the regulation of cell growth, apoptosis, and translation of membrane proteins. It has been shown to play a critical role in the regulation of the growth of cancer cells, and is often expressed at higher levels in these cells compared to normal cells. Therefore, targeting EIF4A1P4 could be an effective way to treat cancer.

In addition, EIF4A1P4 has also been shown to play a critical role in the regulation of apoptosis, which is the process by which cells die naturally. EIF4A1P4 has been shown to regulate the expression of genes involved in cell apoptosis, and has been implicated in the regulation of cell death in various diseases. Therefore, targeting EIF4A1P4 could also be an effective way to treat neurodegenerative diseases.

Biomarker Potential

EIF4A1P4 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its involvement in various cellular processes that are disrupted in these diseases, providing a potential diagnostic approach.

In cancer, EIF4A1P4 has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancers. This has led to the idea that targeting EIF4A1P4 could be an effective way to treat these diseases. In addition, EIF4A1P4 has also been shown to be involved in the regulation of cell signaling pathways, which are often disrupted in cancer cells. Therefore, targeting EIF4A1P4 could also be an effective way to treat cancer by targeting its involvement in these signaling pathways.

In neurodegenerative diseases, EIF4A1P4 has been shown to be involved in the regulation of cellular processes that are involved in the development and progression of these diseases. This has led to the idea that targeting EIF4A1P4 could be an effective way to treat these diseases. In addition, EIF4A1P4 has also been shown to play a critical role in the regulation of protein translation, which is often disrupted in neurodegenerative diseases. Therefore, targeting EIF4A1P4 could also be an effective way to treat these diseases by targeting its involvement in protein translation.

In autoimmune disorders, EIF4A1P4 has been shown to be involved in the regulation of cellular processes that are involved in the development and progression of these diseases. This has led to the idea that targeting EIF4A1P4 could be an effective way to treat these diseases. In addition, EIF4A1P4 has also been shown to play a critical role in the regulation of cell signaling pathways, which is often disrupted in autoimmune disorders. Therefore, targeting EIF4A1P4 could also be an effective way to treat these diseases by targeting its involvement in these signaling pathways.

Conclusion

In conclusion, EIF4A1P4 is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. Its involvement in various cellular processes, including cell growth, apoptosis, and translation of membrane proteins, makes it a potential drug target and biomarker for various diseases. Targeting EIF4A1P4 could be an effective way to treat cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of EIF4A1P4

Protein Name: Eukaryotic Translation Initiation Factor 4A1 Pseudogene 4

The "EIF4A1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4A1P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets